outperform price
bar extra weak explan guid
thesi updat head pki print expect
debat around conserv guidanc outlook context
macro environ messag peer
think pki guid conserv explan around
contribut impact extra week caus confus management guid
organ assum bp contribut
extra week rev neg bp impact margin beg
question extra rev becam dilut top-line think
bp contribut could conserv context point
assum mm contribut rev
revenue base skew toward capital-expenditure less
like benefit extra day context mm
expect extra week seem conserv us see fig
comparison capital-expenditure smaller piec pie vs
second find mention margin
dilut back omx gener solid ex fx
consist qoq back crush margin think
conserv well fundament side
da guid msd posit food expect turn around
msd life increment posit note da
guid assum flat industrials/appli segment
rev could sourc upsid eu turn dx side
everyth seem track euroimmun expect grow
dd guid also assum birth rate continu declin final
convers step also posit us
step right direct understand guidanc
explan could creat nois key driver remain intact us
could potenti upsid surpris reaffirm
outperform rate tweak pt lower
ep due lower omx extra week hw assumpt
seem oner us
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
pleas see guid color market color
bp omx driven gm opex leverag
bp adjust extra week
extra week mm addit revenu like pull forward end
expens extra week offset increment revenu
mm interest expens
average dilut share count mm
faster grow busi higher tax jurisdict
total vanadi instal impli thru yr
incent comp plan
work capit turn expect static
understand shortfal feel confid abil improv convers
healthi funnel current process shipping/instal sever system
also current develop pcr assay corona hope test within week
start particip european tender
impact embed corona viru could drag euroimmun
bp om declin driven extra week result bp drag
organ back extra week impact
extra week revenue pull forward end
apac europ msd
expect vanadi lift europ slightli expect low msd
life slightli soft
food msd driven cannabi y/i growth w/ slight rebound food-ex cannabi exit
da driven life rebound core food
pharma/biotech hsd w/ cisbio dd well deal model
expect cisbio hsd
industrial/environment flat throughout fy expect chang
cannabi revenu
meizhang growth show earli synergi
expect cannabi step growth
increment cautiou life despit fund remain strong
dx comp
vanadi test everi woman w/ high precis low call rate
custom feedback nipt market sizabl grow rapidli
advantag
immunodx strong increment cautiou head
appli genom remain soft hsd
genet test lab drive substanti growth despit continu challeng
expect soft persist pick
growth assumpt go forward
ramp back hire
fda approv gsp kit newborn dmd screen
expect drug discoveri screen reagent tick
greater cross-compani collabor year come
lot room continu omx next year
convers hit next yr
achiev organ increment margin
 remain top prioriti capit deploy esp life dx
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari
analyst luke sergott vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
